NCT07136987View on ClinicalTrials.gov

A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,104

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2031

Study Completion Date

July 31, 2031

Conditions
Tuberculosis
Interventions
DRUG

Metformin

Metformin 500 mg QAM x 1 wk, then 500 mg BID x 1 wk, then 1000 mg QAM and 500 mg QPM, plus standard TB treatment

DIETARY_SUPPLEMENT

N-Acetylcysteine (NAC) Treatment

N-acetylcysteine (NAC) 1800 mg orally twice daily plus standard TB treatment

COMBINATION_PRODUCT

Standard TB treatment

Standard TB treatment

All Listed Sponsors
collaborator

National Institute for Research in Tuberculosis, Chennai, India

UNKNOWN

lead

Open Source Pharma Foundation

OTHER